BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15448009)

  • 21. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis.
    Kyzas PA; Cunha IW; Ioannidis JP
    Clin Cancer Res; 2005 Feb; 11(4):1434-40. PubMed ID: 15746043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.
    Kröger N; Milde-Langosch K; Riethdorf S; Schmoor C; Schumacher M; Zander AR; Löning T
    Clin Cancer Res; 2006 Jan; 12(1):159-68. PubMed ID: 16397038
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TP53 gene in blood plasma DNA of tumor patients.
    Schlechte HH; Stelzer C; Weickmann S; Fleischhacker M; Schulze G
    Ann N Y Acad Sci; 2004 Jun; 1022():61-9. PubMed ID: 15251941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary versus radiation-associated craniofacial osteosarcoma: Biologic and clinicopathologic comparisons.
    McHugh JB; Thomas DG; Herman JM; Ray ME; Baker LH; Adsay NV; Rabah R; Lucas DR
    Cancer; 2006 Aug; 107(3):554-62. PubMed ID: 16795069
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression of ferredoxin reductase predicts outcome in patients with metastatic colorectal cancer treated by 5-fluorouracil plus leucovorin.
    Ichikawa W; Ooyama A; Toda E; Sugimoto Y; Oka T; Takahashi T; Shimizu M; Sasaki Y; Hirayama R
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):794-801. PubMed ID: 16528528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oropharyngeal squamous cell carcinoma treated with radiotherapy or radiochemotherapy: prognostic role of TP53 and HPV status.
    Fallai C; Perrone F; Licitra L; Pilotti S; Locati L; Bossi P; Orlandi E; Palazzi M; Olmi P
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1053-9. PubMed ID: 19577857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TP53 overexpression in radiation-induced osteosarcoma of the rabbit mandible.
    Buchholz TA; McCabe K; Cobb J; Haroff H; Prestidge BR; Ehler WJ
    Radiat Res; 1999 Mar; 151(3):278-82. PubMed ID: 10073665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
    Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
    Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma.
    Burke L; Flieder DB; Guinee DG; Brambilla E; Freedman AN; Bennett WP; Jones RT; Borkowski A; Caporaso NA; Fleming M; Trastek V; Pairolero P; Tazelaar H; Midthun D; Jett JR; Liotta LA; Travis WD; Harris CC
    Clin Cancer Res; 2005 Jan; 11(1):232-41. PubMed ID: 15671551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Four tumour markers for urinary bladder cancer--tissue polypeptide antigen (TPA), HER-2/neu (ERB B2), urokinase-type plasminogen activator receptor (uPAR) and TP53 mutation.
    Ecke TH; Schlechte HH; Schulze G; Lenk SV; Loening SA
    Anticancer Res; 2005; 25(1B):635-41. PubMed ID: 15816639
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma.
    Russo A; Corsale S; Agnese V; Macaluso M; Cascio S; Bruno L; Surmacz E; Dardanoni G; Valerio MR; Vieni S; Restivo S; Fulfaro F; Tomasino RM; Gebbia N; Bazan V
    J Cell Physiol; 2006 Jan; 206(1):181-8. PubMed ID: 15965904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
    George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
    J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic role of E2F1 and members of the CDKN2A network in gastrointestinal stromal tumors.
    Haller F; Gunawan B; von Heydebreck A; Schwager S; Schulten HJ; Wolf-Salgó J; Langer C; Ramadori G; Sültmann H; Füzesi L
    Clin Cancer Res; 2005 Sep; 11(18):6589-97. PubMed ID: 16166437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accumulation of p53 protein in pterygia is not accompanied by TP53 gene mutation.
    Schneider BG; John-Aryankalayil M; Rowsey JJ; Dushku N; Reid TW
    Exp Eye Res; 2006 Jan; 82(1):91-8. PubMed ID: 16005868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective reporting biases in cancer prognostic factor studies.
    Kyzas PA; Loizou KT; Ioannidis JP
    J Natl Cancer Inst; 2005 Jul; 97(14):1043-55. PubMed ID: 16030302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multimarker model to predict outcome in tamoxifen-treated breast cancer patients.
    Linke SP; Bremer TM; Herold CD; Sauter G; Diamond C
    Clin Cancer Res; 2006 Feb; 12(4):1175-83. PubMed ID: 16489071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.
    Le Calvez F; Mukeria A; Hunt JD; Kelm O; Hung RJ; Tanière P; Brennan P; Boffetta P; Zaridze DG; Hainaut P
    Cancer Res; 2005 Jun; 65(12):5076-83. PubMed ID: 15958551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
    Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
    Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.